Bone Biologics Statistics
Total Valuation
Bone Biologics has a market cap or net worth of $2.55 million. The enterprise value is -$3.50 million.
Important Dates
The last earnings date was Friday, November 14, 2025, after market close.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 1.80 million shares outstanding. The number of shares has increased by 390.51% in one year.
| Current Share Class | 1.80M |
| Shares Outstanding | 1.80M |
| Shares Change (YoY) | +390.51% |
| Shares Change (QoQ) | +221.82% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 0.96% |
| Float | 1.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.00
| Current Ratio | 19.00 |
| Quick Ratio | 18.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.46% and return on invested capital (ROIC) is -51.70%.
| Return on Equity (ROE) | -80.46% |
| Return on Assets (ROA) | -48.68% |
| Return on Invested Capital (ROIC) | -51.70% |
| Return on Capital Employed (ROCE) | -67.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.97M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.93% in the last 52 weeks. The beta is 0.51, so Bone Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -81.93% |
| 50-Day Moving Average | 2.13 |
| 200-Day Moving Average | 3.56 |
| Relative Strength Index (RSI) | 26.91 |
| Average Volume (20 Days) | 37,199 |
Short Selling Information
The latest short interest is 24,812, so 1.38% of the outstanding shares have been sold short.
| Short Interest | 24,812 |
| Short Previous Month | 40,068 |
| Short % of Shares Out | 1.38% |
| Short % of Float | 1.39% |
| Short Ratio (days to cover) | 0.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.06M |
| Pretax Income | -3.95M |
| Net Income | -3.95M |
| EBITDA | n/a |
| EBIT | -4.06M |
| Earnings Per Share (EPS) | -$4.77 |
Full Income StatementBalance Sheet
The company has $6.05 million in cash and n/a in debt, giving a net cash position of $6.05 million or $3.37 per share.
| Cash & Cash Equivalents | 6.05M |
| Total Debt | n/a |
| Net Cash | 6.05M |
| Net Cash Per Share | $3.37 |
| Equity (Book Value) | 6.02M |
| Book Value Per Share | 3.35 |
| Working Capital | 6.02M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.33M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.33M |
| FCF Per Share | -$1.85 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
